cancer drugs News
Most Popular cancer drugs Story
Is Avastin really worth the cost?
Is Avastin an object lesson in weighing the costs of an expensive drug against its benefits? Some experts think so, and the New York Times over the weekend took an extensive look at the controversy. Read more...
Latest Headlines
- September 7, 2011
- August 22, 2011
- July 20, 2011
- June 8, 2011
- June 6, 2011
- May 19, 2011
- April 13, 2011
- December 27, 2010
- November 30, 2010
- November 24, 2010
- November 9, 2010
- November 1, 2010
- October 20, 2010
- October 12, 2010
- July 9, 2010
- April 5, 2010
- January 27, 2010
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
